$SERA

Inglis Tiffany Eul Davis sold $728 of SERA

Inglis Tiffany Eul Davis (Chief Medical Officer) sold 362 shares of SERA PROGNOSTICS, INC. (SERA) at $2.01 on 2026-06-11.

Original reporting
SEC EDGAR · Inglis Tiffany Eul Davis
Published Jun 15, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SERA
Neutral
medium confidence
Mentioned
$SERA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

An officer (Chief Medical Officer) executed an open-market sale; the filing provides transparency on insider behavior but does not include operational or financial performance updates.

02

Market read

This is a disclosed insider sale; it may slightly affect sentiment but lacks fundamental catalysts in the text.

03

What to watch

Traders may want to compare with prior insider transactions, total insider ownership, and whether other executives/owners are selling or buying around the same window.

Relevance 3/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-15 (sale dated 2026-06-11)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERANeutralMedium confidence
Context

SEC Form 4 shows CMO Inglis Tiffany Eul Davis sold 362 shares of SERA at $2.01/share on 2026-06-11.

Expected impact

Likely minimal near-term price impact; watch for follow-on insider activity or unusual volume.

Evidence & confidence

The filing is a small, disclosed sale by an officer with no stated 10b5-1 plan, but insider sales alone rarely drive material repricing without corroborating fundamentals.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Absence of a pre-arranged 10b5-1 plan could be interpreted as less “mechanical,” but the disclosed size is still small and may not reflect fundamentals.

Key entities

  • SERA PROGNOSTICS, INC.

    Company whose insider transaction is disclosed on Form 4.

  • Inglis Tiffany Eul Davis

    Chief Medical Officer who sold 362 shares at $2.01/share.

Related articles